In class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma - Supplementary Material

Supplementary Figure S1. Study design and timelinesSupplementary Figure S2. Populations for the IRd and V-based cohorts Selected from US MM-6 and INSIGHT MM.Supplementary Table S1. Patient baseline and disease characteristics before IPTW.Supplementary Table S2. Duration of treatment with individual agents in the IRd and V-based IPTW-weighted cohorts.Supplementary Table S3. Stem cell transplant and subsequent PI therapy in the V-based IPTW-weighted cohort.<br>

补充图S1：研究设计与时间线<br>补充图S2：从美国MM-6与INSIGHT MM研究中筛选得到的IRd方案组及基于V方案组的研究人群<br>补充表S1：IPTW（逆概率治疗加权，Inverse Probability of Treatment Weighting）前的患者基线与疾病特征<br>补充表S2：经IPTW加权的IRd方案组与基于V方案组的单药治疗持续时长<br>补充表S3：基于V方案且经IPTW加权队列中的干细胞移植及后续蛋白酶体抑制剂（Proteasome Inhibitor，PI）治疗情况